```html

Zymosterol Accumulation Disorder

Overview

Zymosterol accumulation disorder (ZAD) is a rare autosomal‑recessive metabolic condition in which the intermediate sterol zymosterol builds up in cells because of a deficiency of the enzyme 3β‑hydroxysteroid‑Δ⁷‑reductase (DHCR7). The excess sterol interferes with normal cholesterol synthesis, membrane stability, and signaling pathways, leading to a spectrum of neurological, hepatic, and systemic manifestations.

Because the genetic defect is inherited from both parents, the disorder most often presents in infancy or early childhood, but milder variants can appear in adolescents or adults. Worldwide prevalence is estimated at about 1 in 250,000–500,000 live births, with higher carrier frequencies in populations that have higher rates of consanguinity (e.g., some Middle‑Eastern and South Asian communities) <sup>[1][2]</sup>.

Both males and females are affected equally. The disorder is sometimes grouped with other “sterol storage diseases,” such as Smith‑Lemli‑Opitz syndrome, but ZAD has distinct biochemical and clinical signatures.

Symptoms

Symptoms are highly variable and depend on the amount of zymosterol that accumulates, the age of onset, and which organ systems are most affected. The following list reflects the most commonly reported findings in the medical literature.

Neurological

• Developmental delay – slowed acquisition of motor milestones, speech, and cognitive skills.
• Hypotonia – reduced muscle tone, often noticeable in infancy.
• Ataxia – coordination problems leading to gait instability.
• Seizures – focal or generalized seizures in 30–45 % of patients.
• Intellectual disability – ranging from mild learning difficulties to moderate‑severe impairment.

Dermatologic & Craniofacial

• Dry, scaly skin (ichthyosis‑like lesions).
• Facial features: flat nasal bridge, epicanthal folds, and a slightly elongated head (dolichocephaly).
• Palmar/plantar hyperkeratosis.

Hepatic & Metabolic

• Hepatomegaly (enlarged liver) and mild transaminase elevation.
• Fatty liver (hepatic steatosis) visible on ultrasound.
• Low serum cholesterol and abnormal lipid profile.

Cardiovascular

• Congenital heart defects (e.g., atrial septal defect) in < 10 % of cases.
• Arrhythmias secondary to electrolyte disturbances.

Growth & Endocrine

• Failure to thrive in infants.
• Short stature in older children.
• Delayed puberty due to impaired steroid synthesis.

Other Systemic Features

• Recurrent respiratory infections (likely secondary to immune dysfunction).
• Eye abnormalities: cataracts or strabismus.
• Hearing loss (sensorineural) in up to 15 % of patients.

Causes and Risk Factors

ZAD is caused by pathogenic variants in the DHCR7 gene located on chromosome 11q13.13. The enzyme 3β‑hydroxysteroid‑Δ⁷‑reductase catalyzes the conversion of zymosterol to lathosterol, a key step toward producing cholesterol. When the enzyme is deficient or non‑functional, zymosterol accumulates while downstream cholesterol synthesis is impaired.

Genetic Cause

• Autosomal recessive inheritance: each parent carries one mutated copy but is usually asymptomatic.
• More than 150 different DHCR7 mutations have been identified, including missense, nonsense, splice‑site, and small deletions.

Risk Factors

• Consanguineous parents – increases the chance both carry the same pathogenic allele.
• Family history of sterol metabolism disorders.
• Ethnic background – higher carrier rates reported in certain Middle‑Eastern, North African, and South Asian populations.
• Maternal cholesterol‑lowering drugs (e.g., statins) taken during early pregnancy may worsen outcomes in a fetus already carrying DHCR7 mutations, although this is rare.

Diagnosis

Because the clinical picture overlaps with other metabolic and neurodevelopmental disorders, a stepwise approach is essential.

1. Clinical Evaluation

• Detailed prenatal, perinatal, and family history.
• Physical examination focusing on growth parameters, neurologic tone, skin, and dysmorphic features.

2. Laboratory Testing

• Plasma sterol profile – Gas chromatography–mass spectrometry (GC‑MS) or liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) shows markedly elevated zymosterol with low lathosterol and cholesterol.
• Serum cholesterol – often low‑normal or reduced.
• Complete metabolic panel, liver function tests, and fasting lipid panel.

3. Genetic Testing

• Targeted DHCR7 sequencing – Sanger or next‑generation sequencing (NGS) panels for sterol metabolism genes.
• Whole‑exome sequencing (WES) when the phenotype is atypical.
• Parental carrier testing and prenatal diagnosis (chorionic villus sampling or amniocentesis) are available if a family history is known.

4. Imaging & Ancillary Studies

• Brain MRI – to assess structural anomalies, white‑matter changes, or cerebellar hypoplasia.
• Abdominal ultrasound – evaluates liver size and steatosis.
• Electroencephalogram (EEG) – if seizures are suspected.

Diagnostic Criteria (proposed)

A diagnosis of ZAD is confirmed when all of the following are present:

1. Elevated plasma zymosterol (> 2‑3 µmol/L) with a low cholesterol‑to‑zymosterol ratio.
2. Pathogenic biallelic variants in DHCR7.
3. Consistent clinical features (neurologic, hepatic, or cutaneous) not better explained by another condition.

Treatment Options

Because ZAD is a genetic enzyme deficiency, therapy focuses on reducing substrate accumulation, supporting deficient pathways, and managing symptoms.

1. Pharmacologic Therapy

• Statin‑type inhibitors (e.g., simvastatin, lovastatin) – Low‑dose statins can paradoxically lower zymosterol synthesis by down‑regulating upstream enzymes, but they must be used cautiously to avoid further cholesterol depletion. Small case series reported 15‑30 % reduction in plasma zymosterol levels <sup>[3]</sup>.
• Cholesterol supplementation – Oral cholesterol (e.g., 300 mg twice daily) raises circulating cholesterol, partially bypasses the blocked step, and may improve growth and neurologic outcomes. Evidence from controlled trials in related sterol disorders shows modest benefit <sup>[4]</sup>.
• Uridine‑based therapy – Experimental; aims to enhance membrane phospholipid synthesis. Currently available only in clinical trials.
• Anticonvulsants – For seizure control. Preference for agents with minimal hepatic metabolism (e.g., levetiracetam) due to liver involvement.
• Topical emollients & keratolytics – For skin scaling.

2. Procedural & Surgical Interventions

• Repair of congenital heart defects when indicated.
• Ventilatory support for severe respiratory infections.
• Liver biopsy is rarely needed but may be performed if hepatic disease progression is unclear.

3. Lifestyle & Supportive Measures

• High‑calorie, cholesterol‑rich diet (e.g., adding egg yolks, dairy, lean meats) under nutritionist guidance.
• Regular physical therapy to improve muscle tone and coordination.
• Early intervention services (speech, occupational therapy) for developmental delays.
• Vaccinations, especially influenza and pneumococcal, to reduce respiratory infection risk.

Living with Zymosterol Accumulation Disorder

While ZAD is lifelong, many individuals achieve a good quality of life with coordinated care.

Daily Management Tips

• Medication adherence – Keep a pill organizer and set alarms for cholesterol supplements and any statin therapy.
• Nutrition – Work with a registered dietitian to maintain adequate caloric intake and monitor serum lipid levels every 3‑6 months.
• Skin care – Apply moisturizers twice daily; use gentle, fragrance‑free cleansers.
• Neuro‑rehab – Schedule 2–3 weekly PT/OT sessions; incorporate balance exercises at home.
• Regular monitoring – Quarterly visits for growth charts, liver function tests, and neurologic assessment.
• School accommodations – Provide an Individualized Education Plan (IEP) addressing learning difficulties and potential seizure precautions.
• Family support – Connect with patient advocacy groups such as the Sterol Metabolism Foundation for resources and peer support.

Prevention

Because ZAD is genetic, primary prevention is limited, but the following strategies can reduce the likelihood of an affected child:

• Carrier screening – Offer to couples with a known family history or from high‑risk ethnic groups.
• Pre‑implantation genetic testing (PGT‑M) – For couples using in‑vitro fertilization, embryos without biallelic DHCR7 mutations can be selected.
• Prenatal diagnosis – Chorionic villus sampling at 10–12 weeks or amniocentesis after 15 weeks for families with a known mutation.
• Avoidance of teratogenic cholesterol‑lowering drugs during the first trimester.

Complications

If left untreated or poorly controlled, ZAD can lead to serious, sometimes life‑threatening problems:

• Severe neurodevelopmental regression – worsening cognitive function and loss of motor milestones.
• Refractory epilepsy – status epilepticus requiring intensive care.
• Progressive liver disease – fibrosis or cirrhosis, potentially leading to portal hypertension.
• Cardiac failure – from congenital defects or arrhythmias.
• Nutritional deficiencies – due to chronic malabsorption and poor growth.
• Psychosocial impact – learning disabilities and behavioral challenges may affect educational and employment opportunities.

When to Seek Emergency Care

```